


C646

Chemical Properties

CAS No. : 328968-36-1
 Formula: C₂₄H₁₉N₃O₆
 Molecular Weight: 445.42
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	C646, a histone acetyltransferase inhibitor, inhibits p300 (K _i : 400 nM, in a cell-free assay).
Targets(IC50)	Apoptosis,Epigenetic Reader Domain,Histone Acetyltransferase,Autophagy
In vitro	In the spinal cord, C646 can attenuate mechanical and thermal hyperalgesia, accompanied by the suppression of COX-2 expression. When administered immediately after weak extinction training into the ILPFC, C646 enhances the integration of fear extinction memory.
In vivo	In vitro, C646 at a concentration of 10 μM inhibits p300 by 86%. In castration-sensitive androgen-responsive prostate cancer cell lines, C646 (20 μM) induces apoptosis by interfering with the AR and NF-κB pathways. Furthermore, C646 at 25 μM reduces the acetylation levels of histones H3 and H4 and blocks TSA-induced acetylation. In mouse cells, C646 inhibits the dynamic acetylation of all H3K4me3, spanning locally across promoters and transcription start sites of inducible genes, thereby disrupting the interaction with RNA polymerase II and the activation of these genes.
Kinase Assay	Radioactive assay: IC ₅₀ values for the putative p300 HAT inhibitors are determined using the direct radioactive assay described above. Reactions are performed in 20 mM HEPES (pH 7.9), and contained 5 mM DTT, 80 μM EDTA, 40 μg/ml BSA, 100 μM H4-15, and 5 nM p300. Putative inhibitors are added over a range of concentrations, with DMSO concentration kept constant (<5%). Reactions are incubated at 30°C for 10 min, then initiated with addition of a 1:1 mixture of 12C-acetyl-CoA and 14C-acetyl-CoA to 20 mM. After 10 min at 30°C, reactions are quenched with 14% SDS (w/v). All concentrations are screened in duplicate. Gels are run, washed, dried, and exposed to a PhosphorImager plate, and production of Ac-H4-15 quantified to obtain IC ₅₀ s.
Cell Research	Histone acetylation assays in mouse cells. C3H10T1/2 mouse fibroblasts are grown in DMEM with 10% FCS at 37°C with 6% CO ₂ . Confluent cultures are rendered quiescent in DMEM with 0.5% FCS for 18-20 hr prior to treatment. Cells are treated with the following compounds: TSA (10 ng/ml [33 nM]), C646 (25 μM), C37 (25 μM). Antibodies are used at the following concentrations: total H3 (1:10000; ab7834; Abcam); H4K12ac (1:2500; 06-761; Upstate). Rabbit anti-H3K9ac (1:10000) antibodies are generated in-house. Histones are isolated from cells by acid extraction, separated by SDS and acid-urea polyacrylamide gel electrophoresis and analyzed by western blotting.(Only for Reference)

Solubility Information

Solubility	DMSO: 18.5 mg/mL (41.53 mM), Heating is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.45 mg/mL (1.01 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2451 mL	11.2254 mL	22.4507 mL
5 mM	0.449 mL	2.2451 mL	4.4901 mL
10 mM	0.2245 mL	1.1225 mL	2.2451 mL
50 mM	0.0449 mL	0.2245 mL	0.449 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Bowers EM, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. *Chem Biol.* 2010 May 28;17(5):471-82.
- Wang S, Lin Y, Gao L, et al. PPAR- γ integrates obesity and adipocyte clock through epigenetic regulation of Bmal1. *Theranostics.* 2022, 12(4): 1589.
- Yu G, Chen W, Li X, et al. TWIST1-EP300 Expedites Gastric Cancer Cell Resistance to Apatinib by Activating the Expression of COL1A2. *Analytical Cellular Pathology.* 2022, 2022.
- Santer FR, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. *Mol Cancer Ther.* 2011 Sep;10(9):1644-55.
- Xu X, et al. C646 Protects Against DSS-Induced Colitis Model by Targeting NLRP3 Inflammasome. *Front Pharmacol.* 2021 Jul 12;12:707610.
- Pan X, Zhang W, Wang L, et al. KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. *Molecular Oncology.* 2023
- Liang G, He Z, Peng H, et al. Cigarette smoke extract induces the senescence of endothelial progenitor cells by upregulating p300. *Tobacco Induced Diseases.* 2023, 21.
- Marek R, et al. *J Neurosci.* 2011, 31(20), 7486-7491.
- Zhu XY, et al. *Mol Pain.* 2012, 8(84)

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481